Merck

The world’s first pill to treat COVID-19 set for approval

Merck and Merck and Ridgeback Biotherapeutics today announced that the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months. The submission is based on positive results